Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

INGN-201. Introgen Therapeutics.

I Brukner1

  • 1Galileo Genomics, Montreal, Canada. ibrukner@hotmail.com

Current Opinion in Investigational Drugs (London, England : 2000)
|March 15, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

OvaRex (AltaRex).

IDrugs : the investigational drugs journal·2005
Same author

Cellular proteins prevent antisense phosphorothioate oligonucleotide (SdT18) to target sense RNA (rA18): development of a new in vitro assay.

Biochemistry·2000
Same author

Differential behavior of curved DNA upon untwisting.

Proceedings of the National Academy of Sciences of the United States of America·1997
Same author

Trinucleotide models for DNA bending propensity: comparison of models based on DNaseI digestion and nucleosome packaging data.

Journal of biomolecular structure & dynamics·1995
Same author

Sequence-dependent bending propensity of DNA as revealed by DNase I: parameters for trinucleotides.

The EMBO journal·1995
Same author

Mutational analysis of DNase I-DNA interactions: design, expression and characterization of a DNase I loop insertion mutant with altered sequence selectivity.

Protein engineering·1995
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Introgen gained global rights for p53 gene therapy development and commercialization, including INGN-201. This strategic move builds upon existing p53 patents and collaborations for cancer treatment advancements.

Area of Science:

  • Oncology
  • Gene Therapy
  • Intellectual Property

Background:

  • Introgen's collaboration with Aventis was restructured in April 2001.
  • Introgen secured worldwide development and commercial rights for p53 programs and gene therapy products.

Purpose of the Study:

  • To detail Introgen's expanded role in p53-based gene therapy.
  • To highlight the intellectual property portfolio supporting p53 gene therapy development.

Main Methods:

  • Review of collaboration agreements and patent awards.
  • Analysis of intellectual property related to p53 gene therapy and DNA damaging agents.

Main Results:

  • Introgen obtained exclusive worldwide rights for p53 gene therapy products, including INGN-201.

Related Experiment Videos

  • Introgen was awarded a patent for adenovirus vector production (US-06194191).
  • Key patents related to p53 and DNA damaging agents were issued to Introgen and the University of Texas System.

    • Conclusions:

    • The restructured agreement enhances Introgen's position in p53 gene therapy.
    • A strong patent portfolio supports the commercialization of p53-based cancer treatments.